Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer

R. Yates Coley, Scott L. Zeger, Mufaddal Mamawala, Kenneth J. Pienta, H. Ballentine Carter

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Background: Active surveillance (AS) is an alternative to curative intervention, but overtreatment persists. Imperfect alignment of prostate biopsy and Gleason score after radical prostatectomy (RP) may be a contributing factor. Objective: To develop a statistical model that predicts the post-RP Gleason score (pathologic Gleason score [PGS]) using clinical observations made in the course of AS. Design, setting, and participants: Repeated prostate-specific antigen measurements and biopsy Gleason scores from 964 very low-risk patients in the Johns Hopkins Active Surveillance cohort were used in the analysis. PGS observations from 191 patients who underwent RP were also included. Outcome measurements and statistical analysis: A Bayesian joint model based on accumulated clinical data was used to predict PGS in these categories: 6 (grade group 1), 3 + 4 (grade group 2), 4 + 3 (grade group 3), and 8-10 (grade groups 4 and 5). The area under the receiver operating characteristic curve (AUC) and calibration of predictions was assessed in patients with post-RP Gleason score observations. Results and limitations: The estimated probability of harboring a PGS >6 was <20% for most patients who had not experienced grade reclassification or elected surgery. Among patients with post-RP Gleason score observations, the AUC for predictions of PGS >6 was 0.74 (95% confidence interval, 0.66-0.81), and the mean absolute error was 0.022. Conclusions: Although the model requires external validation prior to adoption, PGS predictions can be used in AS to inform decisions regarding follow-up biopsies and remaining on AS. Predictions can be updated as additional data are observed. The joint modeling framework also accommodates novel biomarkers as they are identified and measured on AS patients. Patient summary: Measurements taken in the course of active surveillance can be used to accurately predict patients' underlying prostate cancer status. Predictions can be communicated to patients via a decision support tool and used to guide clinical decision making and reduce patient anxiety. Accurate predictions of the unobservable full prostate Gleason scores for patients in active surveillance can be used to inform a shared decision-making process and to reduce patient anxiety. Predictions can be communicated in a clinical setting with a decision support tool.

Original languageEnglish (US)
JournalEuropean Urology
StateAccepted/In press - 2016


  • Active surveillance
  • Precision medicine
  • Prostate cancer
  • Risk prediction

ASJC Scopus subject areas

  • Medicine(all)
  • Urology


Dive into the research topics of 'Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer'. Together they form a unique fingerprint.

Cite this